

VIRTUAL PHARMACEUTICAL AND MEDICAL DEVICE PRICING AND PAYMENT TRANSFORMATION SUMMIT

JUNE 16 – 19, 2026

www.pharmapaymentsummit.com



Agenda-at-a-Glance

(Draft dated March 11, 2026; Subject to Change)

DAY 1: TUESDAY, JUNE 16, 2026

LAYING THE FOUNDATION FOR THE REST OF THE SUMMIT: GP 101 — AN OVERVIEW OF GOVERNMENT DRUG PRICING PROGRAMS

Review the Core Government Programs that Provide Prescription Drug Benefits to Over Half of the American Public

- Medicaid, Medicare, The VA Federal Supply Program and the 340B Program
- How the Programs are Structured in Order to Provide Benefits to Specific Populations
- Requirements for Pharmaceutical Manufacturers
- The Overlap and Dependence on Commercial Contracting and Distribution
- Key Compliance Considerations

Panel Discussion — The Evolving Landscape of Drug Pricing in the US, Navigating the Terminology and Assessing the Impacts on Manufacturers

- New ASP Reporting Requirements under the 2026 Medicare Physician Fee Schedule
- 340 Rebate Model
- Effectuating the MFP
- IRA Price Negotiations
- The Generous Model
- The Consolidated Appropriations Act
- Globe & Guard
- The Role of Compliance and Managing Risks
- The False Claims act & Anti-Kickback Statute
- The Focus on Bona Fide Service Fees by the OIG and CMS
- The Role of the Pricing Committee
- What GP Compliance Looks Like

DAY 1 ADJOURNMENT

DAY 2: WEDNESDAY, JUNE 17, 2026

MORNING: AN OVERVIEW OF DRUG PRICING IN THE US & THE IMPLICATIONS OF ACTUAL AND THREATENED PHARMACEUTICAL TARIFFS

Overview of the Current State of Play in Trump Administration Drug Pricing Policy and Negotiations

CMS Keynote Address: A Fireside Chat on Trump Administration Pharmaceutical Pricing Policy and Models

Roundtable on the Implications of Actual and Threatened US Pharma Tariffs

Tariff Compliance Issues for Pharma and Device Companies

AFTERNOON: MOST FAVORED NATIONS/INTERNATIONAL REFERENCE PRICING

Overview of Most Favored Nations/International Reference Pricing Initiatives in the US

CMMI Keynote Address: CMS Center for Medicare and Medicaid Innovation MFN Models:

- Medicare Part B: Global Benchmark for Efficient Drug Pricing Model (GLOBE)
- Medicare Part D: Guarding US Medicare Against Rising Drug Costs Model (GUARD)
- Medicaid: GENERating Cost Reductions for U.S. Medicaid Model (GENEROUS)
- Medicare & Medicaid: Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth Model (BALANCE) (Access to GLP1)

An In-depth Analysis of the BALANCE, GENEROUS, GLOBE and GUARD Models

Implementing the GENEROUS Model: Financial and Operational Issues

Implementing the GLOBE and GUARD Models: Financial and Operational Issues

Day 2 Adjournment

DAY 3: THURSDAY, JUNE 18, 2026

MORNING: DIRECT TO CONSUMER (DTC), DIRECT TO EMPLOYER (DTE), COMPANY PLATFORMS, COMMERCIAL PLATFORMS, TRUMPRx, COMPLIANCE AND LEGAL ISSUES

Overview of Direct to Consumer (DTC)/Direct to Patient (DTP) and Direct to Employer (DTE) Pharma Sales Models

New Business Models to Meet Patients Where They Are

Legal and Compliance Issues Formation, Operation and in Participation in DTC/DTP and DTE Prescription Drug Platforms

FDA Regulation of Direct-to-Consumer Advertising

DTC Promotion at a Crossroads: The Evolving Landscape of Regulatory and Legal Policy

AFTERNOON: THE INFLATION REDUCTION ACT MEDICARE DRUG PRICE NEGOTIATION PROGRAM

Background and Overview of Medicare Drug Price Negotiation Program

CMS Medicare Drug Price Negotiation Program Keynote Address

Medicare Drug Price Negotiation Program Roundtable

State Prescription Affordability Boards & State Drug Price Transparency and Reporting Update

Update on Litigation relating to 340B, Medicare Drug Price Negotiation Program and against Administration Most Favored Nations Pricing Initiatives

Day 3 Adjournment

DAY 4: FRIDAY, JUNE 19, 2026

MORNING: MEDICAID REBATES, MEDICARE FAIR PRICES, 340B, PBMS, SPILLOVER TO THE COMMERCIAL MARKET

Joint CMS and HRSA Keynote on Medicaid Rebates, Medicare Fair Price and 340B Program

Medicaid Rebates, Medicare Fair Price Updates & 340B Update Roundtable

The Role of PBMs in Pharma and Device Pricing, Payment and Cost Containment

The new PBM Law and FTC's "Landmark" Settlement with Pharmacy Benefit Manager Express Scripts: Impact on Pharma

Will There be Spillover Effects in the Commercial Market

The Future of Pharmaceutical and Medical Device Pricing and Payment

Day 4 Adjournment